SLC5A2 and diabetes mellitus: They showed a significantly decreased prevalence in men with diabetes mellitus treated with SGLT-2 inhibitors vs. men without one (2.28% vs. 2.54%; odds ratio: 0.89; 95%-CI:0.86–0.94).